Related references
Note: Only part of the references are listed.Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel
Sheng-Chieh Tseng et al.
BIOCHEMICAL PHARMACOLOGY (2013)
The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes
Brielan B. Smiechowski et al.
DIABETES CARE (2013)
Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Paul A. Bunn
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
Peter J. Mazzone et al.
BMC CANCER (2012)
Antidiabetes Drugs Correlate With Decreased Risk of Lung Cancer: A Population-Based Observation in Taiwan
Shih-Wei Lai et al.
CLINICAL LUNG CANCER (2012)
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Impact of metformin on survival
Craig J. Currie et al.
DIABETES CARE (2012)
Metformin and the Risk of Cancer Time-related biases in observational studies
Samy Suissa et al.
DIABETES CARE (2012)
Metformin does not alter the risk of lung cancer: A case-control analysis
Michael Bodmer et al.
LUNG CANCER (2012)
Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Hiroshi Noto et al.
PLOS ONE (2012)
Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
Matthew J. Martin et al.
CANCER DISCOVERY (2012)
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
F. Morgillo et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic Influence of Metformin as First-Line Chemotherapy for Advanced Nonsmall Cell Lung Cancer in Patients With Type 2 Diabetes
Ben-Xu Tan et al.
CANCER (2011)
Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell Types
Dimitrios Iliopoulos et al.
CANCER RESEARCH (2011)
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Maria M. Mihaylova et al.
NATURE CELL BIOLOGY (2011)
Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo
C. Algire et al.
ONCOGENE (2011)
Obesity and Cancer Risk: Recent Review and Evidence
Karen Basen-Engquist et al.
CURRENT ONCOLOGY REPORTS (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
Diabetes and Cancer: A Consensus Report
Edward Giovannucci et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea DeCensi et al.
CANCER PREVENTION RESEARCH (2010)
Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis
Regan M. Memmott et al.
CANCER PREVENTION RESEARCH (2010)
New Users of Metformin Are at Low Risk of Incident Cancer A cohort study among people with type 2 diabetes
Gillian Libby et al.
DIABETES CARE (2009)
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
Jingxiang Huang et al.
BIOCHEMICAL JOURNAL (2008)
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Xu Huang et al.
BIOCHEMICAL JOURNAL (2008)
Thienopyridone Drugs Are Selective Activators of AMP-Activated Protein Kinase β1-Containing Complexes
John W. Scott et al.
CHEMISTRY & BIOLOGY (2008)
Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer
Pamela J. Goodwin et al.
CLINICAL BREAST CANCER (2008)
IGF and Insulin Receptor Signaling in Breast Cancer
Antonino Belfiore et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra et al.
ONCOGENE (2008)
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Francesco Frasca et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2008)
Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress
Rintaro Okoshi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer
Anna Marie Mulligan et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Prevalence and specificity of LKB1 genetic alterations in lung cancers
S. Matsumoto et al.
ONCOGENE (2007)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Mahvash Zakikhani et al.
CANCER RESEARCH (2006)
Rheb inhibits C-Raf activity and B-Raf/C-Raf heterodimerization
Magdalena Karbowniczek et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
AMP-activated protein kinase signaling in metabolic regulation
Yun Chau Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin
SL Bowker et al.
DIABETES CARE (2006)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Diabetes and the risk of lung cancer
GC Hall et al.
DIABETES CARE (2005)
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
JW Lee et al.
ONCOGENE (2005)
Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status
DG Hardie
ENDOCRINOLOGY (2003)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
Management of cellular energy by the AMP-activated protein kinase system
DG Hardie et al.
FEBS LETTERS (2003)
AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling.
DR Bolster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study
PJ Goodwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
